SURGICAL AORTIC
VALVE SOLUTIONS
TISSUE HEART VALVES (THV)

 

The Abbott portfolio of surgical aortic valves includes stented tissue valves and mechanical valves that are designed to rebuild healthier hearts.

TISSUE HEART VALVES (THV)

EPIC™ AORTIC STENTED TISSUE VALVE

The Epic™ Platform has been proven over time and defined by strong hemodynamics, intuitive implantability, and a future-facing design that gives you and your patients more choices when it comes to preserving long-term treatment paths.


TREATING TODAY, PRESERVING TOMORROW

This generation of the Epic™ Platform has been built on the Biocor™ legacy of excellent durability, proven performance and unparalleled implantability—and reimagined with the future of transcatheter interventions in mind.

It is the surgical valve platform that gives you and your patients more choices when it comes to preserving long-term treatment paths.

 

FIND OUT MORE ABOUT:

AORTIC STENOSIS TREATMENT OPTIONS

AORTIC

  • Can withstand up to approximately 8 atm pressure during balloon valvuloplasty procedures1
  • Internally mounted leaflets and low stent post height reduce coronary obstruction2

HEAR WHAT SURGEONS FROM AROUND THE WORLD THINK ABOUT THE EPIC™ VALVE
 

Eric Charbonneau, MD, FRCSC

Vinod Thourani, MD

Taichi Sakaguchi, MD

Sven Lehmann, MD, MBA, HCM

Streamlined customizable implantation
  • Stent symmetry eliminates the need for specific orientation3
  •  Flexible polymer stent offers more forgiving insertion and seating
  • Short rinse time of 2 x 10 seconds3
  • Epic™ Platform cuff options allow for secure suture placement while limiting suture drag and parachuting forces
     
Exceptional durability across patient populations

LINX™ ANTICALCIFICATION (AC) TREATMENT MAY IMPROVE LONG-TERM PERFORMANCE AND DURABILITY.*

10 YEARS

97.3 ± 0.5%†
Freedom from SVD, All patient ages (Epic™ Aortic Valve)4

98.6 ± 0.8%†
Freedom from SVD, All patient ages (Epic™ Aortic & Epic™ Mitral Valve)4


SVD: structural valve deterioration.
*There is no clinical data currently available that evaluates the long-term impact of AC tissue treatment in humans.
†From stand-alone aortic or mitral valve replacements.

 

Connext
TV

CONNECT TO THE LATEST
IN STRUCTURAL HEART
THERAPY

Find out more

TV

Epic™ HCP testimonial

Epic™ Mitral & Supra Aortic stented tissue valves HCP testimonial

Epic™ Mitral Valve

Epic™ Mitral stented tissue valve with Linx™ AC technology

Webinar: Aortic & Mitral Valve Disease

Webinar 2022: Management of aortic and mitral valve disease

EACTS 2022: SMV repair vs replacement

EACTS 2022 Symposium: Surgical Mitral Valve Repair versus Replacement in the Modern Era of Transcatheter Valve Interventions.

References
  1. Allen KB, Chhatriwalla AK, Cohen DJ, et al. Bioprosthetic valve fracture to facilitate transcatheter valve-in-valve implantation. Ann Thorac Surg. 2017;104(5):1501–1508.
    doi.org/10.1016/j.athoracsur.2017.04.007.
  2. Edelmann JJ, Khan JM, Rogers T, et al. Valve-in-valve TAVR: state-of-the-art review. Innovations(Phila). 2019;14(4):299–310.
    doi.org/10.1177/1556984519858020.
  3. Epic™ Plus Instructions for Use.
  4. Jawad K, Lehmann S, Koziarz A, et al. Midterm results after St Jude Medical Epic porcine xenograft for aortic, mitral, and double valve replacement. J Cardiac Surg.
    2020;35(8): 1769–1777.
    doi.org/10.1111/jocs.14554.
  5. Guler N, Ozkara C, Akyol A. Left ventricular outflow tract obstruction after bioprosthetic mitral valve replacement with posterior mitral leaflet preservation. Tex Heart Inst J.
    2006;33(3):399–401.
    www.ncbi.nlm.nih.gov/pmc/articles/PMC1592274/.
  6. Vyavahare N, Hirsch D, Lerner E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Circulation. 1997:95(2);479–488.
    doi.org/10.1161/01.CIR.95.2.479.
  7. Kelly SJ, Ogle MF, Carlyle WC, et al. Biocompatibility and calcification of bioprosthetic heart valves. Presented at Society for Biomaterials, Sixth World Biomaterials Congress
    Transaction. May 2000:1353.
  8. Frater RWM, Seifter E, Liao K, et al. Chapter 8. In: Gabbay, S, Wheatley DJ, eds. Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses.
    1st ed. Silent Partners, Inc; 1997:105–113.
  9. Vyavahare NR, Hirsch D, Lerner E, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein
    structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40(4):577–585.
    doi.org/10.1002/(SICI)1097-4636(19980615)40:4%3C577::AID-JBM9%3E3.0.CO;2-C.

© Abbott 2023. All rights reserved. 9-EH-5-14458-01 08-2023

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.